factually
Index/Organizations/CLARITY-AD

CLARITY-AD

Fact-Checks

3 results
Feb 1, 2026
Most Viewed

How have recent Phase III anti‑amyloid readouts correlated amyloid plaque reduction with clinical benefit?

Recent Phase III readouts show a clear group‑level relationship: antibodies that produce large, sustained reductions in amyloid PET signal have tended to produce modest but statistically significant s...

Jan 14, 2026
Most Viewed

How do anti‑amyloid antibodies like lecanemab and donanemab differ in trial design, efficacy and safety outcomes for early AD?

Lecanemab and donanemab are two recently approved anti‑amyloid monoclonal antibodies tested in large, randomized trials in early Alzheimer’s disease that both produced substantial amyloid PET clearanc...

Nov 6, 2025

What is lecanemab and what FDA approval status and stages does it have?

Lecanemab, marketed as LEQEMBI or Leqembi, is a humanized IgG1 monoclonal antibody that targets aggregated amyloid‑beta protofibrils and plaques and is approved to treat (mild cognitive impairment or ...